Evidence map›Paper›PMID 24489673›Full record

ArticlePloS one2014

Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.

William D Finkle, Sander Greenland, Gregory K Ridgeway, John L Adams, Melissa A Frasco, Michael B Cook, Joseph F Fraumeni, Robert N Hoover

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03678233 (Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients), which is not on this map. Cited by 260 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
260citing papers in PubMed, 11 pooled it
78.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03678233 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients

TypeinterventionalSponsorUniversity Hospital, Clermont-FerrandRan2019 to 2025Enrolled30ConditionsHypermetabolism in ICU, Loss of Muscle Mass, Functional Disability After ICU, ICU Acquired HypogonadismArmsAndroGel 16.2 mg/L
3 · Its place in the literature

Who cites it

260 citing papers in PubMed, 11 syntheses or guidelines pooled it, 717 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Testosterone replacement in men with sexual dysfunction.The Cochrane database of systematic reviews · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.The Journal of clinical endocrinology and metabolism · 2018
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

200 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

William D FinkleConsolidated Research, Inc., Los Angeles, California, United States of America.
Sander GreenlandDepartment of Epidemiology and Department of Statistics, University of California, Los Angeles, California, United States of America.
Gregory K RidgewayConsolidated Research, Inc., Los Angeles, California, United States of America.
John L AdamsConsolidated Research, Inc., Los Angeles, California, United States of America.
Melissa A FrascoConsolidated Research, Inc., Los Angeles, California, United States of America.
Michael B CookDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Joseph F FraumeniDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Robert N HooverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Consolidated Edison (United States) · USNational Cancer Institute · USUniversity of California, Los Angeles · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

backgroundAn association between testosterone therapy (TT) and cardiovascular disease has been reported and TT use is increasing rapidly.

methodsWe conducted a cohort study of the risk of acute non-fatal myocardial infarction (MI) following an initial TT prescription (N = 55,593) in a large health-care database. We compared the incidence rate of MI in the 90 days following the initial prescription (post-prescription interval) with the rate in the one year prior to the initial prescription (pre-prescription interval) (post/pre). We also compared post/pre rates in a cohort of men prescribed phosphodiesterase type 5 inhibitors (PDE5I; sildenafil or tadalafil, N = 167,279), and compared TT prescription post/pre rates with the PDE5I post/pre rates, adjusting for potential confounders using doubly robust estimation.

resultsIn all subjects, the post/pre-prescription rate ratio (RR) for TT prescription was 1.36 (1.03, 1.81). In men aged 65 years and older, the RR was 2.19 (1.27, 3.77) for TT prescription and 1.15 (0.83, 1.59) for PDE5I, and the ratio of the rate ratios (RRR) for TT prescription relative to PDE5I was 1.90 (1.04, 3.49). The RR for TT prescription increased with age from 0.95 (0.54, 1.67) for men under age 55 years to 3.43 (1.54, 7.56) for those aged ≥ 75 years (p trend = 0.03), while no trend was seen for PDE5I (p trend = 0.18). In men under age 65 years, excess risk was confined to those with a prior history of heart disease, with RRs of 2.90 (1.49, 5.62) for TT prescription and 1.40 (0.91, 2.14) for PDE5I, and a RRR of 2.07 (1.05, 4.11). DISCUSSION: In older men, and in younger men with pre-existing diagnosed heart disease, the risk of MI following initiation of TT prescription is substantially increased.

Indexed as

AgedAge FactorsCarbolinesHumansMaleMiddle AgedMyocardial InfarctionPhosphodiesterase 5 InhibitorsPiperazinesPrescription DrugsPurinesRiskSildenafil CitrateSulfonesTadalafilTestosteroneCarbolinesPhosphodiesterase 5 InhibitorsPiperazinesPrescription DrugsPurinesSildenafil CitrateSulfonesTadalafilTestosterone

Identifiers

PMID24489673
PMCPMC3905977
OpenAlexW2156204904

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.